I am a
Home I AM A Search Login

Papers of the Week

2021 Jul 29

Int J Neuropsychopharmacol

Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: A phase 2b, randomized, placebo-controlled, adaptive dose-finding study.


Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, Drevets W
Int J Neuropsychopharmacol. 2021 Jul 29.
PMID: 34324636.


Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated antidepressant effects in a previous exploratory study in patients with major depressive disorder (MDD).